First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study
designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and
preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.